The availability of this new drug specifically targeting the folding and maturation defects of the CFTR protein significantly broadened the therapeutic landscape for CF patients, particularly those with processing-deficient mutations, offering renewed hope and improved outcomes for this population. This evidence concerns the gene CFTR and cystic fibrosis.